Abstract
Capecitabine is an oral fluoropyrimidine carbamate and a prodrug of 5- fluorouracil, used in treatment of colorectal and breast carcinoma, which fail to respond to standard chemotherapies. A variety of muco-cutaneous adverse effects has been recognized. The pathogenesis of such manifestations still remains an enigma though various theories have been proposed. We report a case of localized cutaneous hyperpigmentation of the palms and soles secondary to capecitabine in a woman that underwent sigmoidectomy and was in her second cycle of chemotherapy. Since these drugs causing HFS has become commoner in its use in the recent years, due to its relative ease in administration and the relative unawareness of this syndrome among dermatologists makes it a prudent topic to be reported.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
